
SMG GLP1 โ 10 ยท 10 mg
A once-weekly GLP-1 receptor agonist, and the molecule behind Ozempic and Wegovy. It acts on one receptor where tirzepatide acts on two and retatrutide on three โ less raw power, but the deepest trial record and the longest real-world safety history of the three. If you've never used anything in this family, this is the one to start with.
Includes 10ร sterile insulin syringes + 1 vial of bacteriostatic water, free with your order.
Complete your kit
For research and educational use only. Not for human or veterinary consumption.
- Appetite drops. The hunger signal itself gets quieter. Many people notice it within the first couple of doses, even at the starting dose.
- Food noise goes away. Food stops occupying mental space between meals. This is what people describe first, usually before the scale moves.
- You get full faster and stay full longer. Gastric emptying slows, so a smaller plate becomes enough.
- Cravings for sugar and alcohol fade โ reported consistently, though alcohol is not an approved use.
- Fat loss follows the deficit this makes easy to hold. In STEP 1, adults on 2.4 mg weekly lost an average of 14.9% of bodyweight over 68 weeks, against 2.4% on placebo. STEP 5 showed the loss held at 15.2% for two years on continued treatment.
- It's the only compound in this family with a proven heart benefit in people without diabetes. In SELECT (17,000+ adults with obesity and existing heart disease), semaglutide cut heart attacks, strokes and cardiovascular deaths by 20%. In STEP-HFpEF it improved heart-failure symptoms and walking distance.
Which one should you choose? We sell all three.
| SMG GLP1 (semaglutide) | TZP GLP2 (tirzepatide) | R3TA GLP3 (retatrutide) | |
|---|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Average loss in its main trials | ~15% at 68 weeks | ~20% at 72 weeks | 28.3% at 80 weeks |
| Head-to-head | Lost to tirzepatide in SURMOUNT-5 (โ13.7% vs โ20.2%) | Beat semaglutide | No head-to-head yet |
| Proven beyond weight | Heart events (SELECT), heart failure symptoms | Sleep apnoea | Not yet |
| Approved | Yes โ Ozempic, Wegovy | Yes โ Mounjaro, Zepbound | No |
- Choose SMG GLP1 if it's your first GLP-1, you have 5โ15 kg to lose, you want the compound with the longest safety record, or heart health is part of the reason.
- Choose TZP GLP2 if you want more effect than semaglutide with what most people describe as a smoother stomach, or semaglutide stalled for you.
- Choose R3TA GLP3 if you want the strongest effect available and accept that it is not yet approved anywhere.
It does not replace a calorie deficit. Nothing in this catalog does. It makes the deficit easy to hold instead of exhausting.
It does not protect your muscle. In the STEP 1 body-scan substudy, roughly 40% of the weight lost was classed as lean mass. DXA overstates true muscle loss (it counts water and organ mass too), but the direction is real. Eat about 1.6 g of protein per kg of bodyweight a day and lift weights two to four times a week from week one.
It does not keep working after you stop. In the STEP 1 extension, people who came off semaglutide had regained two-thirds of what they lost within a year, and their blood pressure and blood sugar drifted back toward where they started. In STEP 4, people switched to placebo after 20 weeks regained 6.9% while those who continued lost another 7.9%. Plan your exit โ a slow taper with training and protein habits already in place โ before you start.
It is not the strongest option. Tirzepatide beat it head-to-head. If you need 20%+ loss, semaglutide alone is unlikely to get you there at the doses on this page.
๐ Do not use this if:
- You or anyone in your family has had medullary thyroid cancer, or you have MEN2. This is the boxed warning on the label โ semaglutide causes thyroid C-cell tumours in rodents, and whether it does in humans is unknown.
- You are pregnant, breastfeeding, or planning a pregnancy within two months. Stop at least two months before trying to conceive โ it takes that long to clear.
- You have had pancreatitis, have severe gastroparesis, or have a history of an eating disorder โ speak to a doctor first.
- You take insulin or a sulfonylurea (risk of low blood sugar), have diabetic eye disease, or take levothyroxine or other narrow-dose oral medication โ that's a doctor conversation before starting, not necessarily a blocker.
Common, mostly in the days after each dose increase (Wegovy label, 2.4 mg vs placebo):
- Nausea โ 44% vs 16%. Usually settles within a week of a step-up.
- Diarrhoea โ 30% vs 16%
- Vomiting and constipation โ 24% each
- Abdominal pain, bloating, reflux, sulphur burps
- Headache, tiredness, dizziness in the first weeks
- Eating too little โ set reminders and hit your protein first
Less common:
- Gallstones and gallbladder inflammation โ more likely with fast weight loss
- A faster resting heart rate
- Hair shedding around months 3โ4, linked to the speed of weight loss
- Injection site redness or itching
Stop and see a doctor:
- Severe abdominal pain that radiates to your back โ possible pancreatitis
- Pain under the right ribs, fever, or yellowing of your eyes or skin โ possible gallbladder problem
- Vomiting where you cannot keep fluids down, or very little urine โ dehydration can injure the kidneys
- Severe constipation with a swollen belly and no wind โ bowel obstruction (ileus) has been reported after approval
- Sudden loss of vision in one eye โ NAION, an optic-nerve event the EMA confirmed in 2025 as a very rare side effect (about one extra case per 10,000 people per year)
- A lump in your neck, a hoarse voice that won't go away, or trouble swallowing
- Swelling of your face, lips or throat, or difficulty breathing
- New or worsening low mood or any thoughts of self-harm. Large reviews by the EMA (2024) and the FDA (2026) found no causal link, and the FDA removed the warning from the label in January 2026 โ but a change in mood during a big change in eating always deserves a conversation.
โ ๏ธ Before any surgery, sedation or endoscopy, tell the doctor you're on this. Slowed stomach emptying raises the risk of inhaling stomach contents under anaesthesia.
Discontinuation for side effects ran 6.8% vs 3.2% on placebo. Most people who escalate slowly do not stop.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
10 mg vial + 2 mL bacteriostatic water = 5 mg/mL
| Dose | Volume | Units (U-100) |
|---|---|---|
| 0.25 mg | 0.05 mL | 5 |
| 0.5 mg | 0.10 mL | 10 |
| 1 mg | 0.20 mL | 20 |
| 1.7 mg | 0.34 mL | 34 |
| 2.4 mg | 0.48 mL | 48 |
โ Use exactly 2 mL. It's the only volume where every step of the label schedule is a whole number of clicks and the top dose still fits under the pen's 60-click limit. At 1 mL, the starting dose would be 2.5 clicks. At 3 mL, it would be 7.5.
โ ๏ธ Clicks are not milligrams. The FDA has recorded hospitalisations from people drawing five to twenty times their intended semaglutide dose because they mixed up units, millilitres and milligrams. Read the table, count the clicks, and never copy a "units" number from someone else's vial โ it only works at this exact concentration.
Inject the water slowly down the inside wall of the vial. Swirl gently, never shake. It should be completely clear with no particles. Refrigerate at 2โ8 ยฐC and use within four weeks.
Draw past the line, tap out bubbles, push back to the line.
The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.
Maximum per injection: 100 units (1 mL)
Once weekly, subcutaneous, same day each week. Abdomen, thigh or upper arm, rotating sites. With or without food, any time of day.
| Weeks | Dose | Units (U-100) | Used in 4 weeks |
|---|---|---|---|
| 1โ4 | 0.25 mg | 5 | 1 mg |
| 5โ8 | 0.5 mg | 10 | 2 mg |
| 9โ12 | 1 mg | 20 | 4 mg |
| 13โ16 | 1.7 mg | 34 | 6.8 mg |
| 17 onwards | 2.4 mg | 48 | 9.6 mg |
This is the Wegovy label schedule. 0.25 mg is a starting dose, not a working dose โ it exists to let your stomach adapt.
You don't have to climb to the top. If you're losing roughly 0.5โ1% of bodyweight a week and side effects are mild, stay where you are. Move up only when the loss stalls for two to three weeks and you're tolerating the current step. If a step-up makes you sick, drop back for another four weeks before trying again. Never raise the dose early to finish a vial.
Missed a dose? If your next one is more than two days away, take it now. If it's less than two days away, skip it and carry on. Missed two or more weeks in a row? Restart one step lower.
Honest note on this vial size
One 10 mg vial holds 40 weeks of the starting dose โ but once mixed, it has a four-week refrigerated window. The fridge, not the milligrams, decides how many vials you need:
| Stage | Used from the vial | Left over at 4 weeks |
|---|---|---|
| 0.25 mg ร 4 | 1 mg | 9 mg โ discard |
| 0.5 mg ร 4 | 2 mg | 8 mg โ discard |
| 1 mg ร 4 | 4 mg | 6 mg โ discard |
| 1.7 mg ร 4 | 6.8 mg | 3.2 mg โ discard |
| 2.4 mg ร 4 | 9.6 mg | 0.4 mg โ discard |
So the real number is one vial per four-week stage at every dose. An 8-week start (0.25 then 0.5 mg) is two vials. Climbing to 2.4 mg takes four vials over 16 weeks, then one more every four weeks at maintenance. Don't stretch a vial past four weeks to save the leftover โ sterility and potency are what you'd be gambling.
Cycle: judge it at 8โ12 weeks. Trials ran 68โ104 weeks and the weight stayed off only while people stayed on. When you stop, step down over several weeks rather than stopping dead.
- 1ร SMG GLP1 โ 10 ยท 10 mg
- 10ร sterile insulin syringes (free)
- 1ร bacteriostatic water vial (free)
- Compound Guide โ printed, included free
Semaglutide has the largest and longest trial record of any compound in this catalog: the STEP program in obesity (STEP 1โ5, roughly 15% average loss at 2.4 mg, held for two years in STEP 5), SELECT for heart events, STEP-HFpEF for heart failure, and SUSTAIN-6 in type 2 diabetes. It is approved as Ozempic (type 2 diabetes) and Wegovy (weight, cardiovascular risk reduction and fatty liver disease), now also as a daily tablet and a higher 7.2 mg weekly dose in the US. In Indonesia, Wegovy has been registered with BPOM since June 2024 as a prescription medicine.
What we supply is research-grade semaglutide โ the same molecule โ not the branded pharmaceutical pen. The FDA ended the US shortage in February 2025, which closed the window for compounded copies there.
Athletes: semaglutide is on the WADA Monitoring Program โ not prohibited. It remains permitted on the 2027 list.
- Wilding et al., NEJM, 2021 โ STEP 1: 2.4 mg weekly gave โ14.9% body weight vs โ2.4% on placebo over 68 weeks (1,961 adults)
- Wilding et al., Diabetes Obes Metab, 2022 โ STEP 1 extension: one year after stopping, participants had regained two-thirds of the weight they lost
- Rubino et al., JAMA, 2021 โ STEP 4: after 20 weeks on drug, continuing lost a further 7.9% while switching to placebo regained 6.9%
- Garvey et al., Nature Medicine, 2022 โ STEP 5: โ15.2% vs โ2.6% sustained over 104 weeks
- Lincoff et al., NEJM, 2023 โ SELECT: 20% fewer heart attacks, strokes and cardiovascular deaths in 17,000+ adults with obesity and heart disease, no diabetes
- Kosiborod et al., NEJM, 2023 โ STEP-HFpEF: better heart-failure symptoms and walking distance, โ13.3% body weight over 52 weeks
- Marso et al., NEJM, 2016 โ SUSTAIN-6: 26% fewer major cardiovascular events in type 2 diabetes, with a retinopathy-complication signal
- Aronne et al., NEJM, 2025 โ SURMOUNT-5: tirzepatide โ20.2% vs semaglutide โ13.7% head-to-head over 72 weeks
- FDA, Wegovy prescribing information, 2026 โ escalation schedule, boxed thyroid C-cell warning, adverse-event rates
- EMA PRAC, 2025 โ NAION (sudden optic-nerve vision loss) confirmed as a very rare side effect of semaglutide
Every peptide batch we sell is tested by Janoshik Analytical, an independent laboratory. Every vial carries an internal AVERON batch code identifying the lot received; each lot is linked to its published Janoshik report. The report carries the manufacturer's submission/task number, not the AVERON code. Ask us or our driver which report covers your code and open it on the laboratory's own website before paying. In our own-driver zone, the team shows you the vial and the report for that batch before payment.
A lab report handed to you by a seller and a lab report you can verify yourself are not the same thing. That's why we publish ours.
View COA on Janoshik








